1. Personalized Medicine in Psychiatry
Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report 
Erin Green, Andrea N. Goldstein-Piekarski, Alan F. Schatzberg, A. John Rush, Jun Ma, Leanne Williams 
Personalized Medicine in Psychiatry  
Volume 1, Pages (March 2017)
DOI: /j.pmip
Copyright © Terms and Conditions

2. Fig. 1
Predicted probabilities of remission for each treatment at different levels of Body Mass Index (BMI). Probabilities were calculated at the midpoint of the normal range (21.7kg/m2), overweight (27.5kg/m2), obese class I (32.5kg/m2), obese class II (37.5kg/m2) and at two points within the range of obese class III (42.5kg/m2 and 50kg/m2). Of note, the relationship between BMI and prediction of remission was only significant for venlafaxine-XR. However, predicted probabilities are shown for each treatment arm here.
Personalized Medicine in Psychiatry  2017 1, 65-73DOI: ( /j.pmip )
Copyright © Terms and Conditions

3. Fig. 2
Predicted probabilities of remission for males and females collapsed across treatment at differing levels of Body Mass Index (BMI).
Personalized Medicine in Psychiatry  2017 1, 65-73DOI: ( /j.pmip )
Copyright © Terms and Conditions

4. Fig. 3
Flow chart demonstrating the predicted probability for every combination of sex, obesity classification calculated at the midpoint of the normal range (21.7kg/m2), overweight (27.5kg/m2), obese class I (32.5kg/m2), obese class II (37.5kg/m2) and obese class III (42.5kg/m2). Predicted probabilities lower than 40% are highlighted in red and probabilities greater than 70% are highlighted in green.
Abbreviations: NM=normal; OW=overweight; OB=obese; ESC=escitalopram; SER=sertraline; VEN=venlafaxine-XR.
Personalized Medicine in Psychiatry  2017 1, 65-73DOI: ( /j.pmip )
Copyright © Terms and Conditions